Search
Physician-scientist Samuel Singer studies the genomic alterations that define new targets for therapy in sarcoma. I am a surgical oncologist who specializes in the diagnosis and treatment of soft tissue sarcoma. I have extensive experience with this group of cancers, and am one of just a few surgeons in the world focused solely on treating sarcoma patients. My years of experience have enabled me to devise surgical techniques that improve the ability to completely remove these tumors. In addition to my clinical sarcoma practice, I conduct laboratory research to develop new methods to improve the diagnosis and treatment of sarcoma. I lead both a National Cancer Institute Specialized Program in Research Excellence (SPORE) and the Sarcoma Genome Project.
Our group, the Laboratory of Experimental Cancer Immunogenomics, is a multi-disciplinary team of cancer scientists working at the intersection of genomics, molecular genetics, animal modeling, and biostatistical data sciences.
Physician-scientist Martin Weiser investigates the mechanisms underlying tumor spread and metastasis and how these mechanisms could be targeted.
The Diver lab studies the physiological roles and molecular mechanisms of understudied membrane-embedded proteins with the goal of revealing novel therapeutic targets for diseases such as pain and cancer.
The Functional MRI Laboratory provides pre-operative planning for patients with brain tumors and studies the clinical applications of advanced neuroimaging techniques for brain tumor imaging.
Derek Tan’s lab studies diversity-oriented synthesis and rational drug design of probes and lead compounds for chemical biology and drug discovery.
Alban Ordureau explores molecular signaling pathways that regulate cellular homeostasis, with a focus on the ubiquitin and autophagy systems.
The Minn Lab investigates how cancers evolve under chronic inflammation and persistent immune pressure to acquire resistance to immunotherapies, with the goal of developing innovative therapies to restore anti-tumor immunity.
Molecular biologist John Maciejowski studies the causes of complex chromosome rearrangements and the patterns of hypermutation that shape cancer genomes.